BRAF Mutation in Langerhans Cell HistiocytosisBRAF Mutation in Langerhans Cell Histiocytosis
Children with Langerhans cell histiocytosis (LCH) and the BRAFV600E mutation may be at greater risk for worse outcomes, including permanent injury and poor short-term response to chemotherapy, according to new research from France. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chemotherapy | Children | Health | Hematology | Histiocytosis | Langerhans Cell Histiocytosis (LCH)